MASHINIi

REGENXBIO Inc..

RGNX.US | Research and experimental development on natural sciences and engineering

REGENXBIO Inc. is a clinical-stage biotechnology company focused on the development, commercialization, and licensing of adeno-associated virus (AAV) gene therapies. The company's gene therapy product candidates are designed to deliver functional genes to cells to address genetic defects or acquired...Show More

Ethical Profile

Mixed.

REGENXBIO focuses on developing gene therapies for serious genetic diseases like Duchenne muscular dystrophy, aiming to address unmet medical needs. However, reports suggest mixed employee sentiment, with Glassdoor reviews averaging 3/5 stars and only 42% recommending the company. Diversity, Equity, and Inclusion scores are 2.8/5. While the CEO pay ratio is a fair 15:1, critics point to the critical need for accessible and affordable therapies. The company maintains a third-party ethics reporting system and its Rockville HQ is LEED Gold certified. Transparency is limited regarding animal testing practices and broader environmental data.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect30
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-40
-100100

Better Health for All

0

No evidence available to assess REGENXBIO Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapies, not a financial institution.

1
The company's core business does not involve lending, insuring, moving, or storing money for consumers or communities.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as they pertain to financial services and their impact on economic opportunity and inclusion.

Fair Pay & Worker Respect

30

REGENXBIO Inc. reported a CEO to median employee pay ratio of 15:1 for the 2024 fiscal year.

1
The CEO's pay was $3,495,826, while the median employee pay was $226,641.
2
The company's Rockville, MD headquarters is LEED Gold certified.
3

Fair Trade & Ethical Sourcing

0

No evidence available to assess REGENXBIO Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No specific, concrete data points were found in the provided articles to assess REGENXBIO Inc. against the defined KPIs for the 'Honest & Fair Business' ethical value. Therefore, no KPIs can be scored.

Kind to Animals

-40

REGENXBIO Inc. conducts animal testing for its medical products and therapies, including preclinical trials and animal models, as required for biological product development and FDA approval.

1
The company states that these animal studies are conducted in accordance with Good Laboratory Practice (GLP) and applicable requirements for the humane use of laboratory animals, including compliance with the Animal Welfare Act.
2
While in vitro testing is mentioned in the context of safety risk assessment,
3
the extent to which non-animal testing methods are employed for product safety and efficacy is not specified, and animal assays appear to dominate the development process.
4

No War, No Weapons

0

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapies. The provided articles explicitly state that the company's business activities are not applicable to defense or arms contracts, nor do they contain data relevant to 'No War, No Weapons' metrics. Specifically, notes that the company is 'not a defense contractor,' and confirms that it 'does not contain any data relevant to the requested metrics for RGNX.US related to arms or defense contracts, peacebuilding, or conflict-related issues.'

1
This indicates that the company's core business does not involve defense or arms-related activities, dual-use technologies, sales to embargoed regimes, or other conflict-related operations.

Planet-Friendly Business

0

No specific, concrete data points were found in the provided articles for any of the Planet-Friendly Business KPIs.

1
Information regarding environmental performance, targets, or initiatives is not available.
2

Respect for Cultures & Communities

0

No specific, concrete data points were found in the provided articles that directly address the KPIs related to 'Respect for Cultures & Communities'. The articles primarily focus on financial performance, clinical trial updates, commercial partnerships, and internal workforce diversity (gender and historically underrepresented minority populations), rather than community engagement, cultural preservation, or local community investment.

Safe & Smart Tech

0

No evidence available to assess REGENXBIO Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

-40

The company engages in multiple initiatives to improve manufacturing yields and is measuring waste generation and emissions to identify reduction opportunities.

1
It has also been locally recognized for its waste reduction and recycling programs.
2
The company uses, handles, and disposes of various biological, chemical, and radioactive substances, stating it believes it is in material compliance with applicable environmental laws.
3
Its Rockville, Maryland headquarters is Leadership in Energy and Environmental Design Gold certified, and its Manufacturing Innovation Center is designed to achieve LEED Silver certification.
4

Own REGENXBIO Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.